A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease

NCT01569516 Phase 2 UNKNOWN

The main purpose of this study is to evaluate the safety and efficacy of Octohydroaminoacridine Succinate tablets and find the optimal dose in patients with mild to moderate Alzheimer's Disease.

Details

Lead sponsor	Changchun Huayang High-tech Co., Ltd
Phase	Phase 2
Status	UNKNOWN
Enrolment	288
Start date	2011-06
Completion	2012-10

Conditions

• Alzheimer's Disease

Interventions

• Octohydroaminoacridine Succinate Tablets
• Octohydroaminoacridine Succinate Tablets
• Octohydroaminoacridine succinate Tablets
• Placebo

Primary outcomes

• Alzheimer's Disease Assessment Scale - Cognitive Subscale — 20weeks

Countries

China